HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Successful treatment of imatinib-resistant acute megakaryoblastic leukemia with e6a2 BCR/ABL: use of dasatinib and reduced-conditioning stem-cell transplantation.

AuthorsS Corm, A Renneville, E Rad-Quesnel, N Grardel, C Preudhomme, B Quesnel
JournalLeukemia (Leukemia) Vol. 21 Issue 11 Pg. 2376-7 (Nov 2007) ISSN: 0887-6924 [Print] England
PMID17554376 (Publication Type: Case Reports, Letter)
Chemical References
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Recombinant Fusion Proteins
  • Thiazoles
  • Imatinib Mesylate
  • Fusion Proteins, bcr-abl
  • Dasatinib
Topics
  • Adult
  • Aged
  • Benzamides
  • Dasatinib
  • Drug Resistance, Neoplasm
  • Female
  • Fusion Proteins, bcr-abl (genetics, physiology)
  • Hematopoietic Stem Cell Transplantation (methods)
  • Humans
  • Imatinib Mesylate
  • Leukemia, Megakaryoblastic, Acute (drug therapy, genetics)
  • Male
  • Middle Aged
  • Piperazines (pharmacology)
  • Pyrimidines (pharmacology, therapeutic use)
  • Recombinant Fusion Proteins (chemistry)
  • Thiazoles (therapeutic use)
  • Transplantation Conditioning
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: